From dissection of fibrotic pathways to assessment of drug interactions to reduce cardiac fibrosis and heart failure
Cardiac fibrosis is characterized by extracellular matrix deposition in the cardiac interstitium, and this contributes to cardiac contractile dysfunction and progression of heart failure. The main players involved in this process are the cardiac fibroblasts, which, in the presence of pro-inflammator...
Saved in:
Main Authors: | Gloria Garoffolo (Author), Maurizio Pesce (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs
by: Hao Shen, et al.
Published: (2022) -
Role of microRNAs in cardiac hypertrophy, myocardial fibrosis and heart failure
by: De-li Dong, et al.
Published: (2011) -
How to treat cardiac dyssynchrony in heart failure with reduced ejection fraction
by: Bogdan Stefan, et al.
Published: (2024) -
The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure
by: Masanori Hirose, et al.
Published: (2017) -
Endostatin in fibrosis and as a potential candidate of anti-fibrotic therapy
by: Zequn Zhang, et al.
Published: (2021)